Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Drugmakers, pharmacies next targets for U.S. opioid settlements

Stock MarketsJul 21, 2021 09:46AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
4/4 © Reuters. FILE PHOTO: Tablets of the opioid-based Hydrocodone at a pharmacy in Portsmouth, Ohio, June 21, 2017. REUTERS/Bryan Woolston/File Photo 2/4

By Brendan Pierson

NEW YORK (Reuters) - With a $26 billion nationwide settlement in sight over claims that the three largest U.S. drug distributors and Johnson & Johnson (NYSE:JNJ) helped fuel a nationwide opioid epidemic, state and local governments will soon turn their attention to pharmacies and a handful of drugmakers.

U.S. state attorneys general are expected to unveil a settlement proposal this week with distributors McKesson Corp (NYSE:MCK), Cardinal Health Inc (NYSE:CAH) and AmerisourceBergen (NYSE:ABC) Corp contributing a combined $21 billion, while Johnson & Johnson would pay $5 billion.

The ultimate settlement price-tag could fluctuate depending on how many state and local governments agree to the deal or reject it to pursue litigation on their own.

More than 3,000 lawsuits, mostly by local governments, have been filed over the opioid crisis against a range of companies for allegedly downplaying the risk of the drugs and for lax controls that allowed the highly addictive painkillers to flood communities.

Excluded from the potential $26 billion deal are pharmacy operators including Walgreens Boots Alliance (NASDAQ:WBA), Walmart (NYSE:WMT) Inc, Rite Aid (NYSE:RAD) Corp and CVS Health Corp (NYSE:CVS), which have been accused of ignoring red flags that opioid drugs were being diverted into illegal channels.

The deal also would not include drugmakers AbbVie Inc (NYSE:ABBV), Teva Pharmaceutical Industries (NYSE:TEVA) Ltd or Endo International (NASDAQ:ENDP) Plc, which have been accused of misleadingly marketing their pain medicines as safe.

Nearly 500,000 people died from opioid overdoses in the United States from 1999 to 2019, according to the U.S. Centers for Disease Control and Prevention. The CDC last week said provisional data showed that 2020 was a record year for overall drug overdose deaths with 93,331, up 29% from a year earlier.

The pharmacies and drugmakers have denied the claims, saying rising opioid prescriptions were driven by doctors, that they followed federal law and that the known risks were included in U.S.-approved labels for the drugs.

News of the proposed nationwide settlement came three weeks into a jury trial in New York, and legal experts said upcoming court proceedings will pressure the remaining defendants to reach a deal.

The drugmakers are currently defending themselves at the New York trial and a trial in Orange County, California, and are expected to face another trial in San Francisco along with the pharmacies later this year. The pharmacies, which settled the New York case shortly before trial, also face an October trial in Ohio.

Endo is scheduled to go to trial next week to assess damages over a lawsuit brought on behalf of Tennessee counties and an infant allegedly born addicted to opioids, in which a judge has already ruled the company liable. District Attorney General Barry Staubus of Tennessee's Sullivan County told WHLJ television that the company offered to settle, but the deal would be limited to that case.

'COMMON GOAL' TO END EPIDEMIC

Richard Ausness, a law professor at the University of Kentucky, said a settlement this week reduces the groups of defendants in the litigation and makes it harder for the remaining companies to blame others.

"It puts pressure on them to reach a deal, especially if the mechanics were formulated in this present settlement,” he said.

Peter Mougey, a lawyer representing the local governments pursuing opioid litigation around the country, said at a news conference to discuss proposed settlements that he was "frustrated" pharmacies were not part of the nationwide deal.

"They've had ample time to assess where they are with their liability, and we all have the common goal of trying to end this opioid epidemic," he said.

The pharmacies did not immediately respond to requests for comment.

In 2019, Teva proposed a settlement in which it would donate addiction treatment drugs that it valued at $23 billion. Industry analysts said the actual cost of the drugs to Teva could be as little as $1.5 billion, however, and plaintiffs' lawyers balked at what they called an inflated valuation.

Joe Rice, another plaintiffs' lawyer, said Teva had not been involved in settlement talks since early 2020 but that plaintiffs hoped to negotiate with them going forward.

Teva said in a statement on Tuesday that it remained "confident" it would reach a deal involving donated drugs, and that it would defend itself against "unfounded claims" in the meantime.

"Now more than ever - with local state government budgets dramatically impacted by COVID - it is clear that donated medicines provide the holistic approach needed for solving the epidemic of addiction," the Israel-based company said.

AbbVie and Endo did not immediately respond to requests for comment on settlement negotiations.

Other settlements are also being negotiated with OxyContin maker Purdue Pharma and generic opioid maker Mallinckrodt (OTC:MNKKQ) Plc now working through the bankruptcy courts to secure support for settlements worth more than $10 billion and $1.6 billion, respectively.

Drugmakers, pharmacies next targets for U.S. opioid settlements
 

Related Articles

BAM Stock: A Canadian Gem Worth a Look
BAM Stock: A Canadian Gem Worth a Look By TipRanks - Sep 27, 2021

Brookfield Asset Management (BAM) is one of those Canadian stocks that can offer you a better bang for your buck. The Toronto-based alternative asset manager provides investors...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email